The overarching theme of our application is to quantify the impact of cancer cell heterogeneity in tumor growth and treatment resistance. It logically extends results from the previous funding period, pointing to phenotypic heterogeneity as key determinant of progression and invasion. We will consider heterogeneity with respect to phenotypic traits (Proliferation, Motility and Metabolism), in the ICBP-43 breast cancer cell line panel and in drug resistant breast, or radiation responsive lung, cancer cell lines. Trait heterogeneity will be quantified primarily by high-content automated microscopy and image processing. Between cell lines, trait variability will be compared as averages and distribution shapes. Within a cell line, ceil-to-cell variability (presumably non-genetic) will be represented as subpopulations by statistical modeling, e.g., bayesian information criteria and clustering algorithms. To estimate adaptability, we will measure trait variation in response to perturbations mimicking tumor microenvironment conditions. This large dataset (3 traits in >50 lines under >10 perturbations) will be input to mathematical and computational predictive models, tracking the fate of individual cancer cells and the microenvironment in space-time during tumor growth. With the experimental component, this suite of theoretical models forms a Center """"""""Backbone"""""""" deployed towards three Projects. Project 1 will quantify adaptive advantage in cancer progression by incorporating cell trait heterogeneity data into mathematical and computational models that exploit evolution dynamics and game theory concepts. Project 2 will measure impact of trait heterogeneity and fitness cost in the rise of breast cancer resistance to first- and second-line drugs (doxorubicin, hormone therapy and HER2 tyrosine kinase inhibitors). Project 3 will attempt to improve and/or predict outcomes of radiation treatment in lung cancer cell lines by coupling experimentally defined radio-phenotype heterogeneity to predictive models. Hypotheses/predictions from Projects 1-3 will be validated in vitro and in mouse tumors, by iteration loops of experimentation and theory. Finally, we will continue education/outreach efforts, e.g., hands-on cancer modeling workshops, to attract physical and biological scientists, especially the brightest of the new generations.

Public Health Relevance

Though central to cancer progression, phenotypic heterogeneity is understudied due to its complexity. Our proposal integrates experimentation and theory to quantify the impact of cell heterogeneity in cancer progression, and deploy novel approaches to cancer drug and radiation resistance. By specializing in Cancer Systems Biology at the subcellular, cellular and tissue scales, we will continue to build a much-needed data and modeling bridge between genetic/molecular and clinical/epidemiological scales.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA113007-10
Application #
8628754
Study Section
Special Emphasis Panel (ZCA1-SRLB-C (J1))
Program Officer
Gallahan, Daniel L
Project Start
2004-09-30
Project End
2015-02-28
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
10
Fiscal Year
2014
Total Cost
$958,904
Indirect Cost
$209,035
Name
Vanderbilt University Medical Center
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Hardeman, Keisha N; Peng, Chengwei; Paudel, Bishal B et al. (2017) Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition. Sci Rep 7:42604
Wooten, David J; Quaranta, Vito (2017) Mathematical models of cell phenotype regulation and reprogramming: Make cancer cells sensitive again! Biochim Biophys Acta 1867:167-175
Udyavar, Akshata R; Wooten, David J; Hoeksema, Megan et al. (2017) Novel Hybrid Phenotype Revealed in Small Cell Lung Cancer by a Transcription Factor Network Model That Can Explain Tumor Heterogeneity. Cancer Res 77:1063-1074
Harris, Leonard A; Frick, Peter L; Garbett, Shawn P et al. (2016) An unbiased metric of antiproliferative drug effect in vitro. Nat Methods 13:497-500
Franco, Omar E; Tyson, Darren R; Konvinse, Katherine C et al. (2016) Altered TGF-?/? signaling drives cooperation between breast cancer cell populations. FASEB J 30:3441-3452
Werner, Benjamin; Scott, Jacob G; Sottoriva, Andrea et al. (2016) The Cancer Stem Cell Fraction in Hierarchically Organized Tumors Can Be Estimated Using Mathematical Modeling and Patient-Specific Treatment Trajectories. Cancer Res 76:1705-13
Gerlee, Philip; Kim, Eunjung; Anderson, Alexander R A (2015) Bridging scales in cancer progression: mapping genotype to phenotype using neural networks. Semin Cancer Biol 30:30-41
Frick, Peter L; Paudel, Bishal B; Tyson, Darren R et al. (2015) Quantifying heterogeneity and dynamics of clonal fitness in response to perturbation. J Cell Physiol 230:1403-12
Nichol, Daniel; Jeavons, Peter; Fletcher, Alexander G et al. (2015) Steering Evolution with Sequential Therapy to Prevent the Emergence of Bacterial Antibiotic Resistance. PLoS Comput Biol 11:e1004493
Broussard, Joshua A; Diggins, Nicole L; Hummel, Stephen et al. (2015) Automated analysis of cell-matrix adhesions in 2D and 3D environments. Sci Rep 5:8124

Showing the most recent 10 out of 89 publications